Mohammad Keykhaei, MD, MPH

1/🚨Excited to share our new study published in @JAMACardio: “Cost Offset With Quadruple Therapy for Heart Failure” jamanetwork.com/journals/jamac… Deeply grateful to Dr. @gcfmd and our amazing team for their unwavering support and mentorship: @SinaRsh @SJGreene_md @NMHheartdoc @boback @ATSandhu @MKittlesonMD @uclaCVfellows @DOM_UCLA @uclaimchiefs @UCLAHealth @dgsomucla #HeartFailure #HFrEF #GDMT

🛠️ ARNI ➕ 🛡️ β-blocker➕ 🧪 MRA ➕ 🍬 SGLT2i Invest: 💊 cost ~ $1 per day Receive: 🏖️ ⤴️ HRQoL ☠️ ⬇️ by 74% HF 🏨 ⬇️ by 85% 🏨 cost saving ~ $64 per day jamanetwork.com/journals/jamac…

Our work was just published in #JACCAdvances! 💻Evaluation of a novel Dashboard Clinic to optimize GDMT in veterans with heart failure: 📍48.5% of patients had GDMT started or recommended 📍Post-intervention GDMT optimization score increased significantly 📍Quadruple therapy use rates jumped from 4.3% to 13.4% The Dashboard Clinic is a viable and potentially effective intervention for improving GDMT optimization in patients with HF, offering a scalable blueprint for dashboard-directed care within a clinical-educational hybrid model 👥 Grateful for the mentorship and guidance from @boback @gcfmd @JeffHsuMD Read more: jacc.org/doi/10.1016/j.… #HeartFailure #Cardiology

The FDA approved a daily pill PCSK9i enlicitide, (Lipfendra) List price will be $315 for a 30-day supply nejm.org/doi/full/10.10… The F.D.A. Approves a New Pill to Slash Cholesterol Levels nytimes.com/2026/07/16/sci… via @NYTimes @kewatson @AnnMarieNavar @rblument1

Dashboard-Directed Intervention to Improve Guideline-Directed Heart Fa... sciencedirect.com/science/articl… @qicong_sheng @gcfmd @JACCJournals @DOM_UCLA @VALosAngeles @JeffHsuMD

@mvaduganathan @SJGreene_md @NMHheartdoc @robmentz @dranulala 💵 Economics: JAMA Cardiology (Keykhaei et al., 2026) modeling 50,000+ Medicare pts full quadruple GDMT could slash HF hospitalizations by ~87% & all-cause by ~61% offsetting ~$10K/patient/yr in hospital costs, landing in NET SAVINGS after drug prices.

@mvaduganathan @SJGreene_md @NMHheartdoc @robmentz @dranulala @MKeykhaeiMD 💊 ARNI ➕ 🛡️ β-blocker ➕ 🧪 MRA ➕ 🍬 SGLT2i = lives saved 🚀 + beds freed 🏥 + dollars back 💸 Don’t wait. Initiate and titrate quadruple GDMT early. Inaction is the expensive option. ⚡ #CardioTwitter #HeartFailure

Thank you to the #BCVS Council for supporting my trip to #AHA18 with an Abstract Travel Award! 🙏🏼 Really enjoyed my first time at the council dinner. A highly esteemed group led by Dr. Joe Wu @StanfordCVI. #AHA18 #AHAEarlyCareerBlogger @AHAMeetings #bruinhearts

Cardio-oncology trials should measure more than ejection fraction. I was joined by Dr. Sara Hurvitz #coauthor and #divisionchief @fredhutch @UW #hemeonc to discuss how patient-reported symptoms and function complement objective CV endpoints—and why standardized definitions matter. #CardioOncology #ClinicalTrials. Read the statement here: ahajournals.org/doi/10.1161/CI… @neerajaiims @montypal @AnaBaracCardio @PGrivasMDPhD

Meta-analysis indicates #Prasugrel provides optimal balance of efficacy and safety for patients after #PCI, with lower major adverse cardiovascular events and stent thrombosis compared with ticagrelor and clopidogrel. ja.ma/4gMyggz

🔥 Amazing talk by Dr. @gcfmd on ACS & NSTEMI management, covering the 2025 AHA/ACC ACS Guidelines, DAPT strategies, risk stratification, and landmark trials! Key takeaways 🧵👇 🫀 PROVE IT–TIMI 22 • Intensive statin (atorvastatin 80 mg) vs moderate (pravastatin 40 mg) after ACS • 16% relative risk reduction in death/MI/revascularization/stroke • LDL goal shifted from <100 → <70 mg/dL based on this trial • Benefit seen as early as 30 days 💊 EPHESUS • Eplerenone vs placebo in post-MI patients with LVEF ≤40% + HF • 15% reduction in all-cause mortality (HR 0.85, p=0.008) • 21% reduction in sudden cardiac death • 23% reduction in HF hospitalizations • Earlier initiation (<7 days) → even greater benefit 🏥 EMPACT-MI • Empagliflozin 10 mg vs placebo within 14 days of acute MI • Primary endpoint (HF hospitalization + death): HR 0.90, p=0.21 — NOT significant • BUT: 23% reduction in first HF hospitalization (HR 0.77) & 33% reduction in total HF hospitalizations • Benefit consistent regardless of diabetes status 📋 DAPT Strategies Post-ACS • Default: DAPT ≥12 months (ASA + P2Y12 inhibitor, ticagrelor/prasugrel preferred) • Bleeding reduction: Early ASA discontinuation → P2Y12 monotherapy (Class 1) • High bleeding risk: Stop ASA or P2Y12 >1 month → SAPT @uclaCVfellows @DOM_UCLA @uclaimchiefs

Quadruple GDMT for #HFrEF = maybe the best ROI in all of medicine: 😌 Fewer symptoms, better QoL
🏥 ↓ HF + all-cause 🏨
❤️ ↓ HF, CV + all-cause ☠️
⏳ +7–10 years of median survival
💰 ~$380/yr generic 💊 ➡️ saves ~$10K/yr vs partial Rx ~$1 a day Prescribe all four 📈

Among patients with spontaneous ICH, prior use of P2Y12 inhibitor monotherapy or in combination with aspirin was associated with more severe strokes and worse clinical outcomes jamanetwork.com/journals/jaman… @DCRINews @YingXian21 @Braindoc_MGH @DLBHATTMD @brianmacgrory @AHAScience

🚨NEW PODCAST🚨 IC-OS experts discuss our joint @CancerCareMASCC statement on preventing & managing cardiovascular disease in cancer patients. @sdent_cardioonc @koczwar 🎧 tinyurl.com/2r5ee9zf #CardioOncology #Cancer #Cardiology #Oncology #HeartHealth

The CARDIO-TTRansform Phase III trial1 for eplontersen in patients with ATTR-CM did not meet the primary efficacy endpoint of the composite outcome of CV mortality and recurrent CV clinical events up to 140 weeks Update on CARDIO-TTRansform astrazeneca.com/media-centre/p…

Join the cardiology community on Roon! roon.com/doctors?utm_so…

Excited to share that our work is now published! Patient-derived iPSC lines from patients with ICI myocarditis and controls provide a foundation for patient-specific disease modeling and precision medicine in cardio-oncology. authors.elsevier.com/sd/article/S18…

@HeartNews Honored to begin as Editor-in-Chief of @CircAHA.🫀 I am grateful to the extraordinary leadership of @josephahill, who set the bar high. The new Circulation team is ready to carry the torch forward. First issue out today: ahajournals.org/toc/circ/curre… @American_Heart #Cardiology #AHA

We’re proud to share that Dr. E. Dale Abel has been elected a fellow of the Royal College of Physicians of Edinburgh, an international honor recognizing his outstanding contributions to medicine, research, education and patient care. Read the full story: uclahs.fyi/4p7cXs6

🎆 Four pillars ➡️ many more years to enjoy fireworks 🎆 #HFrEF 
❤️ ARNi ↓28% ☠️ 
🤍 BB ↓34% 
💙 MRA ↓25% 
⭐ SGLT2i ↓17% 
Large, additive & EARLY benefit: fewer deaths 🫀, fewer admissions 🏥, better QoL, lower cost all for ~$1/day 💊🇺🇸 
#CardioEd #GDMT #HeartFailure

A polypill for heart failure was associated with a significant improvement in cardiac function as compared with enhanced usual care Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial nature.com/articles/s4159… @NMHheartdoc @HeartDocSadiya